Attovia Therapeutics, Inc. ATTO
15.81 USD -0.92 (-5.50%)
At closeNov 12, 2026, 4:00 PM EST
15.81 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
15.41 Day range 16.67
12.94 52-week range 28.00
- YTD
- -27.81%
- 1 year
- -27.81%
News
benzinga.com Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34 Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.
benzinga.com Morgan Stanley Maintains Overweight on Attovia Therapeutics, Raises Price Target to $40 Morgan Stanley analyst Judah Frommer maintains Attovia Therapeutics (NASDAQ:ATTO) with a Overweight and raises the price target from $39 to $40.
seekingalpha.com Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript
benzinga.com Attovia Therapeutics Q3 EPS $(0.76) Misses $(0.50) Estimate Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.50) by 52 percent. This is a 77.91 percent increase over losses of…
globenewswire.com Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in…
marketbeat.com Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials Attovia Therapeutics NASDAQ: ATTO reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with…